Company / Working Capital
MoonLake Immunotherapeutics Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$376.2M
FY2025
5-year range
-$11.5M / $504.2M
FY2021-FY2025
Trend
-16.7%
vs FY2024
Sector context
#117 of 213
Health Care
What the data says
At $376M, MoonLake Immunotherapeutics's working capital ranks #117 of 213 in the Health Care sector. Declined from $504M to $376M over the past 2 years.
Based on SEC 10-K filings.
$376M in FY2025 with a 5-year CAGR of +202.2%.
Declined from $504M to $376M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +76.1%
- 5-Year CAGR
- +202.2%
- 10-Year CAGR
- -
Sector benchmark
#117 of 213 in Health CareTop 55% of 213This company $376.2M Sector average $934.6M
▼
-59.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +202.2%, indicating consistent growth.
- In FY2025, working capital decreased 16.7% year-over-year.
- Ranks #117 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $376.2M | -16.7% |
| FY2024 | $451.8M | -10.4% |
| FY2023 | $504.2M | +632.4% |
| FY2022 | $68.8M | +701.2% |
| FY2021 | -$11.5M | -866.6% |
| FY2020 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026